Answers are grounded in this paper and cite their sources.
High Resolution Image Download MS PowerPoint Slide Preclinical tumor studies are often limited by high variability and small-sample sizes, reducing statistical power, and masking treatment effects. We present an exponential framework that estimates tumor growth rates ( r ) independently of initial burden and introduces Tumor Growth Rate (TGR) matrices to map treatment effects across time windows. Applied to a public xenograft data set and four additional mouse models, exponential fits achieved high agreement with raw data (median R 2 = 0.937). When resampling matched group sizes ( n = 3–7), our approach consistently outperformed conventional end point and daily nonparametric analyses, revealing treatment effects that standard comparisons missed. The framework also predicts tumor weights for animals euthanized early, enabling their inclusion in final analyses and enhancing statistical consistency while advancing the 3Rs principles. To ensure broad adoption, we developed ViVo, an open-source web platform ( gcanudo-barreras.github.io/ViVo-Platform/ ) that provides accessible, standardized analysis of in vivo tumor kinetics and therapeutic efficacy.
No takes yet. Share an insight, caveat, or question.
Canudo‐Barreras et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: